ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with ...
AstraZeneca (AZN) stock is in focus as FDA panel snubs the company's bid to win U.S. nod for camizestrant and backs its ...
14hon MSNOpinion
Opinion: A ‘chop the top’ approach could save Social Security
Some are coalescing around the idea of capping Social Security benefits for top earners.
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...
MedPage Today on MSN
FDA Staff Raises Concerns on Two Cancer Drug Applications
The Oncologic Drugs Advisory Committee will meet for the first time in 9 months ...
Republican lawmakers say they will continue to defer to President Donald Trump, for now, during the fragile ceasefire with ...
AstraZeneca PLC on Friday said it had secured a recommendation for its cancer drug Truqap from US authorities, but failed to secure a majority in favour of its treatment camizestrant. Shares in the ...
1d
Union Pacific argues for its $85B acquisition of Norfolk Southern in new railroad merger application
Union Pacific hopes regulators will be convinced this time that its $85 billion acquisition of Norfolk Southern that it ...
Annual General Meeting of April 29, 2026Belén Garijo appointed as Director and Chief Executive Officer of SanofiParis, April 29, 2026. Sanofi's ...
Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo”), a multi-state cannabis operator, and FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a vertically-integrated, multi-state ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results